Cigna Group (CI) stock analysis
Close on Nov 11, 2026Market cap $79.66BP/E 13.3Yield 2.00%
StockData Score
Prices as of Nov 11, 2026How the score works
Solid16 of 30 checks passed
Cigna passes 16 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 6/6
- Growth
- 2/6
- Past performance
- 3/6
- Financial health
- 2/6
- Dividend
- 3/6
What stands out
Margin of safety over 20%
The price is 21.5% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $301.45 is below our fair value estimate of $383.88.
Revenue growing 10%+ a year
Revenue grew 15.0% a year over the last three fiscal years.
Interest well covered
Operating income covers interest expense 7.1 times.
What to watch
High debt
Debt is 71.8% of shareholders' equity, above the 40% we consider low.
EPS growing under 10% a year
Diluted EPS grew 1.2% a year over the last three fiscal years.
Growing slower than the industry
Revenue grew 6.8% over the last twelve months; the Accident and Health Insurance and Medical median is 6.8%.
Gross margin slipping
Gross margin was 20.7% over the last twelve months, against 23.1% a year earlier.
Valuation6/6
P/E below its 5-year median
Cigna's P/E of 13.3 is below its own 5-year median of 15.6.
P/E below the industry
Cigna's P/E of 13.3 is below the Accident and Health Insurance and Medical median of 21.3.
P/S below the industry
Cigna's price-to-sales of 0.28 is below the Accident and Health Insurance and Medical median of 0.80.
P/B below the industry
Cigna's price-to-book of 1.84 is below the Accident and Health Insurance and Medical median of 2.31.
Trading below fair value
The share price of $301.45 is below our fair value estimate of $383.88.
Margin of safety over 20%
The price is 21.5% below fair value, more than the 20% cushion we look for.
Growth2/6
Revenue growing 10%+ a year
Revenue grew 15.0% a year over the last three fiscal years.
EPS growing under 10% a year
Diluted EPS grew 1.2% a year over the last three fiscal years.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 6.8% over the last twelve months; the Accident and Health Insurance and Medical median is 6.8%.
Guidance raised
Cigna raised its Full Year Ending December 31, 2026 Cigna Healthcare Medical Care Ratio outlook on Jul 30, 2026.
Gross margin slipping
Gross margin was 20.7% over the last twelve months, against 23.1% a year earlier.
Past performance3/6
Return on equity
Needs positive equity and five years of results.
Return on assets over 1%
Return on assets was 3.8%; for a bank or insurer, 1% or more is considered good.
Return on equity above the industry
Cigna's return on equity of 14.1% is above the Accident and Health Insurance and Medical median of 11.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin above the industry
Cigna's net margin of 2.1% is above the Accident and Health Insurance and Medical median of 2.0%.
Financial health2/6
High debt
Debt is 71.8% of shareholders' equity, above the 40% we consider low.
Debt rising against equity
Debt to equity rose from 65.4% five years ago to 71.8%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 30.3% of total debt.
Interest well covered
Operating income covers interest expense 7.1 times.
Short-term assets don't cover short-term debts
Current assets are 0.84 times current liabilities.
Bankruptcy risk (Altman Z)
The Altman model does not apply to insurers.
Dividend3/6
Pays a dividend
Cigna paid dividends worth 2.1% of the share price over the last twelve months.
Yield below Treasuries
The 2.1% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; Cigna yields 2.1%.
Dividend not cut
The dividend per share has not fallen by more than 10% in any of the last 9 fiscal years.
Covered by earnings
Dividends take 27.2% of net income.
Cash-flow cover
Needs dividends paid and free cash flow.
Fair value
How we estimate itOur estimate per share
$383.88
The share price is 21% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 18.5× | 15.6× | 21.3× | $418.46 | 50% |
| P/B | 2.1× | 2.0× | 2.3× | $349.30 | 50% |
| Fair value | $383.88 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 15.6
- Accident and Health Insurance and Medical median 21.3
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $475.99M
- Value traded per 1% price move
- $348.37M
Downside
Low risk
- Typical loss in a bad month
- 9.4%
- Volatility (annualized)
- 27%
- Sharpe ratio, 1 year
- 0.46
- Beta to the S&P 500 (5Y)
- 0.34
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.2% | +15.0% | +11.4% | – | |
| Gross profit | -7.3% | +2.5% | +1.0% | – | |
| Operating income | -2.3% | +2.9% | +2.4% | – | |
| Net income | +73.5% | – | – | – | |
| EPS, diluted | +83.0% | +1.2% | -0.7% | – | |
| Dividend per share | +7.9% | +10.5% | +172.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 14.4% | |
| Return on assets | – | – | 3.8% | |
| Current ratio | – | 0.77 | 0.85 | |
| Debt to equity | – | 0.65 | 0.75 | |
| Net debt to EBITDA | – | 2.07× | 1.99× | |
| Interest coverage | 12.3× | 5.8× | 6.6× | |
| Inventory turnover | – | 35.5× | 30.6× | |
| Capex to revenue | 1.2% | – | – | |
| Diluted shares | 260M | 368M | 269M |
Cash use needs five years of cash flow figures
Cigna does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 2.2% | 1.75× | 3.79× | 14.4% |
| FY2024 | 1.4% | 1.60× | 3.54× | 7.9% |
| FY2023 | 2.6% | 1.32× | 3.26× | 11.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$5.96B
- Cash generatingOperating cash flow above zero$9.60B
- Return on assets improvedROA up on the prior year2.2% → 3.8%
- Earnings backed by cashOperating cash flow above net income$9.60B vs $5.96B
- Less leverageLong-term debt to assets fell18.6% → 19.5%
- Better liquidityCurrent ratio rose0.84 → 0.85
- No dilutionShare count did not rise283M → 269M
- Gross margin improvedGross margin up on the prior year26.15% → 21.79%
- More efficientAsset turnover rose1.62 → 1.76
See a number that looks wrong?